Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Abdul Rafeh Naqash is an advanced fellow in the Early Clinical Trials Development Program and the Developmental Therapeutics Clinic at the National Cancer Institute, Bethesda.
Patient Education Ambassador Program - Rafeh Naqash MD, Understanding Clinical Trials Part 2
dbrock
2020 PEA Program - Rafeh Naqash MD, Clinical Trials Series with Ivy Elkins and Dr. Fumiko Chino MD
Image
Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials.
For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doctors/fumiko-chino).
In these videos, Drs. Naqash and Chino and Ms. Elkins discuss:
-
Are Placebos Used in Phase 1 Clinical Trials? How Does this Differ from Trials in Other Phases?
- Could A Trial Be Right For Me Even If My Doctor Didn't Know About It?
- How Do I Manage Potential Side Effects I Might Experience on a Clinical Trial?
- How Will Being on a Trial Potentially Impact My Daily Life?
- How Much Will a Clinical Trial Cost? How Does the Billing Work, and What About Emergency Treatment and Other Expenses?
- Does A Clinical Trial Have Provisions or Resources for Stress or Mental Health?
- What Happens if I Have To Leave a Clinical Trial?
#clinicaltrial #genentech #lilly #cancerGRACE
To join the conversation, visit https://cancergrace.org/forum.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Image
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.
¡Los vídeos están disponibles BAJO DEMANDA!
Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.
Image
Article
Da click aquí para más información y para registrarte ahora
Online Community
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Recent Comments
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: